We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Affinivax

News List

Affinivax, Astellas’ pneumococcal vaccine wins breakthrough therapy status pharmatimes
July 16, 2021
Affinivax and Astellas’ pneumococcal vaccine candidate ASP3772 has been granted a breakthrough therapy designation by the US Food and Drug Administration (FDA), the companies announced earlier this week.
Affinivax secures $226m in Series C financing to boost MAPS vaccine pipeline pharmaceutical-business-review
January 12, 2021
Clinical-stage biopharmaceutical company Affinivax has secured $226m in Series C financing to advance the development of new vaccines with its multiple antigen presenting system (MAPS) platform.
Astellas and Affinivax’s novel pneumococcal vaccine enters human testing fiercepharma
February 24, 2019
About two years ago, Astellas licensed a novel pneumococcal vaccine technology from Affinivax with eyes on Pfizer’s Prevnar 13. Now, the pair has officially entered human testing.